contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


interview-and-webinar-published-on-annexins-ongoing-phase-2a-study-in-diabetic-retinopathy-and-retinal-vein-occlusion

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Annexin Pharmaceuticals är ett bioteknikbolag som utvecklar läkemedelskandidaten ANXV, baserad på proteinet Annexin A5, för behandling av sjukdomar som kärlskador, inflammation och viss cancer. Bolagets partners är vårdgivare och biopharmabolag och verksamheten är riktad mot globala marknader via forsknings- och licenssamarbeten. Bolaget grundades 2014 och har sitt huvudkontor i Stockholm, Sverige.

Annexin Pharmaceuticals

Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof ...

<div class="mfn-preamble"><p><strong>Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye diseases diabetic retinopathy (DR) and retinal vein occlusion (RVO) and a summary of the year. A webinar about RVO and the Annexin study conducted by Professor Paulo-Eduardo Stanga is also available.</strong></p></div><div class="mfn-body"><p>Annexin has recently announced that the first two patients have been dosed in the ongoing Phase 2a study, which is being conducted at The Retina Clinic in London under the leadership of Professor Paulo-Eduardo Stanga. In the interview, Anders Haegerstrand and Anna Frostegård give an insight into why the study is important, inform about the chosen study design and the type of data that can be expected to show within DR and RVO, as well as how the company's partnership discussions are progressing. <br>The interview can be seen here: <a rel="noopener" href="https://www.redeye.se/research/1143355/annexin-pharma-interview-redeye-speaks-with-ceo-anders-haegerstrand-cso-cmo-anna-frostegard">Redeye interview</a></p><p>Recently, Professor Paulo-Eduardo Stanga at The Retina Clinic held a webinar, <em>Retinal Vein Occlusion: Clinical Features, Current Management, &amp; Future Developments,</em> where he describes RVO and reviews ANXV as a potential treatment for RVO and the ongoing phase 2a study. Information about Annexin's study begins at 15:30 minutes into the video.<br>The webinar can be viewed here: <a rel="noopener" href="https://www.youtube.com/watch?v=i3v76rToEE8&amp;t=1640s">Retinal Vein Occlusion: Clinical Features, Current Management, &amp; Future Developments</a></p></div><div class="mfn-footer mfn-contacts mfn-b9db9aee869a"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Anders Haegerstrand, CEO <br>Phone: +46 (0)70 575 50 37 <br>Mail: <a rel="noopener" href="mailto:anders.haegerstrand@annexinpharma.com">anders.haegerstrand@annexinpharma.com</a></p></div><div class="mfn-footer mfn-about mfn-d80162962aba"><p><strong class="mfn-heading-1">About Annexin Pharmaceuticals AB</strong><br>Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5.<br>The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fde73991-9e16-4aad-abf7-ae41d67494ff/interview-and-webinar-published-on-annexins-ongoing-phase-2a-study-in-diabetic-retinopathy-and-retinal-vein-occlusion.pdf" class="mfn-generated mfn-primary">Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion</a></p></div>

Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion